Trial intelligence / Profile preview

Phase II study of mXELOXIRI plus a molecular targeted drug as first-line therapy for initially unresectable metastatic colorectal cancer

ChiCTR1900023289Phase 2Recruiting

Sponsor

First Affiliated Hospital, Zhejiang University School of Medicine

Start

Jul 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1